Published in EMBO Molecular Medicine · View the paper (DOI)
Researchers have identified a new biomarker associated with the activation of an innate immune response to neural damage during early stages of Alzheimer's disease. The concentration of a specific segment of the protein TREM2 in cerebrospinal fluid is significantly elevated in early stages of the disease.
Coverage from 2 institutions